Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta-cell function in pancreatic adenocarcinoma

D Basso1, M Plebani, P Fogar

  • 1Istituto di Medicina di Laboratorio, Universita degli Studi di Padova Padua, Italy.

Pancreas
|May 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European guidelines on diagnosis and treatment of phenylketonuria: First revision.

Molecular genetics and metabolism·2025
Same author

Hook-effect in MAGLUMI immunoassay for serum anti-GAD antibodies in neurological disorders: When "wrong" matrix is the right choice.

Clinica chimica acta; international journal of clinical chemistry·2024
Same author

Menstrual changes after COVID-19 vaccine administration: a systematic review.

European review for medical and pharmacological sciences·2023
Same author

Calcitonin levels in autoimmune atrophic gastritis-related hypergastrinemia.

Journal of endocrinological investigation·2023
Same author

Paradoxical GH increase after oral glucose load in subjects with and without acromegaly.

Journal of endocrinological investigation·2023
Same author

Long-term use of carglumic acid in methylmalonic aciduria, propionic aciduria and isovaleric aciduria in Italy: a qualitative survey.

European review for medical and pharmacological sciences·2022

Pancreatic cancer patients show impaired beta-cell function, similar to type I diabetics, with no C-peptide increase after glucagon stimulation. This dysfunction may contribute to hyperglycemia in pancreatic cancer.

Area of Science:

  • Endocrinology
  • Oncology
  • Metabolic Disorders

Background:

  • Pancreatic cancer is frequently associated with hyperglycemia.
  • The underlying mechanisms, particularly beta-cell dysfunction, require further elucidation.
  • Understanding beta-cell response is crucial for managing metabolic complications in cancer patients.

Purpose of the Study:

  • To assess beta-cell function in pancreatic cancer patients using the glucagon stimulation test.
  • To compare beta-cell response in pancreatic cancer with type I diabetes mellitus, type II diabetes mellitus, and healthy controls.
  • To investigate the relationship between altered beta-cell function and hyperglycemia in pancreatic adenocarcinoma.

Main Methods:

  • Glucagon stimulation test administered with 1-mg i.v. glucagon injection.

Related Experiment Videos

  • Serum C-peptide levels measured before and after glucagon injection.
  • Comparative analysis across four groups: pancreatic cancer, type I diabetes, type II diabetes, and healthy controls.

    • Main Results:

    • Pancreatic cancer patients exhibited low basal C-peptide levels and no significant C-peptide increase post-glucagon stimulation.
    • Type I diabetics showed low basal C-peptide and no significant increase, while type II diabetics and controls had normal/increased basal levels and significant increases.
    • Impaired beta-cell secretory capacity was evident in pancreatic cancer patients.

    Conclusions:

    • Pancreatic cancer is associated with significant beta-cell dysfunction, characterized by an inadequate response to glucagon.
    • This impaired beta-cell function likely contributes to the hyperglycemia observed in patients with pancreatic adenocarcinoma.
    • The findings highlight the metabolic impact of pancreatic cancer on endocrine function.